▎ 摘　　要

Dendrimers capped with amino groups (DEN) are grafted to graphene oxide (GO) nanosheets for subsequent functionalization of GO with gadolinium diethylene triamine pentaacetate (Gd-DTPA) and prostate stem cell antigen (PSCA) monoclonal antibody (mAb). The as-prepared GO-DEN(Gd-DTPA)-mAb exhibits very low cytotoxicity, negligible hemolytic activity, and no perceptible toxic effects in mice. GODEN(Gd-DTPA)-mAb can specifically target PSCA over-expressed cancer cells to give a significant T1-weighted contrast enhancement effect. The in vivo magnetic resonance imaging results indicate that GODEN(Gd-DTPA)-mAb can be used as a targeted contrast agent for prostate tumor imaging. GO-DEN(GdDTPA)- mAb can be efficiently loaded with doxorubicin hydrochloride (DOX), and the resulting GODEN(Gd-DTPA)-mAb/DOX exhibits enhanced cytotoxicity to PC-3 cells due to good targeting performance. By following the PC-3 tumor growth in mouse model after intravenous administration of GODEN(Gd-DTPA)-mAb/DOX, it is demonstrated that GO-DEN(Gd-DTPA)-mAb can targetedly deliver anticancer drugs to malignant prostate tumors and inhibit tumor growth. (C) 2016 Elsevier Ltd. All rights reserved.